TG Therapeutics (TGTX) stock jumped 10.2% on high trading volume, driven by strong sales growth.

From Nasdaq: 2025-03-17 05:33:00

TG Therapeutics (TGTX) shares surged 10.2% to $40.84, driven by high trading volume. Sales of their product Briumvi soared over 200% to $313 million in 2024, with a target of $540 million for this year. Expected earnings per share is $0.19, representing a 371.4% increase, with revenues expected at $117.83 million.

Cue Biopharma (CUE) closed 1.8% lower at $0.96, with a consensus EPS estimate of -$0.16 for the upcoming report. The stock has a Zacks Rank of #3 (Hold). Zacks Research Chief highlights a top stock set to double, with a fast-growing customer base and innovative solutions. Download the free report for more information.



Read more at Nasdaq: Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?